Search
ProMIS Neurosciences Inc
PMNAdd to Watchlist
13.350USD
-0.100-0.74%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
119.72MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.74%
5 Days
+26.78%
1 Month
+37.20%
6 Months
+87.11%
Year to Date
+95.60%
1 Year
+23.53%
Key Figures
13.880Open
13.880High
44.96KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.50%Turnover Ratio
13.450Prev. Close
13.050Low
439.69KTurnover
43.08P/E Static
1.97P/B
0.00%Div Yield TTM
-100.21%ROA
39.75052wk High
0.88Volume Ratio
2.78MNet Profit
8.97MShares
-18.6002EPS TTM
-0.17Beta
-115.73%ROE
6.27052wk Low
6.17%Amplitude
--Gross Margin
119.72MMarket Cap
6.00Reward/Risk
6.37%Risk Rate
TradingKey Stock Score of ProMIS Neurosciences Inc
Currency: USD Updated: 2026-07-02Key Insights
ProMIS Neurosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 98 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ProMIS Neurosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
ProMIS Neurosciences Inc Highlights
StrengthsRisks
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -0.72, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.50M shares, increasing 43.86% quarter-over-quarter.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
35.500
Target Price
+163.94%
Upside Space
ProMIS Neurosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ProMIS Neurosciences Inc Info
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Ticker SymbolPMN
CompanyProMIS Neurosciences Inc
CEOWarma (Neil K)
Websitehttps://www.promisneurosciences.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of ProMIS Neurosciences Inc (PMN)?
The current price of ProMIS Neurosciences Inc (PMN) is 13.35.
What is the symbol of ProMIS Neurosciences Inc?
The ticker symbol of ProMIS Neurosciences Inc is PMN.
What is the 52-week high of ProMIS Neurosciences Inc?
The 52-week high of ProMIS Neurosciences Inc is 39.75.
What is the 52-week low of ProMIS Neurosciences Inc?
The 52-week low of ProMIS Neurosciences Inc is 6.27.
What is the market capitalization of ProMIS Neurosciences Inc?
The market capitalization of ProMIS Neurosciences Inc is 119.72M.
Is ProMIS Neurosciences Inc (PMN) currently rated as Buy, Hold, or Sell?
According to analysts, ProMIS Neurosciences Inc (PMN) has an overall rating of Buy, with a price target of 35.50.
What is the Earnings Per Share (EPS TTM) of ProMIS Neurosciences Inc (PMN)?
The Earnings Per Share (EPS TTM) of ProMIS Neurosciences Inc (PMN) is -22.61.